26 November 2019
CooperVision’s MiSight contact lens has become the first contact lens to be approved for myopia management by the US Food and Drug Administration (FDA).
The FDA has consented to the use of the contact lens to slow the progression of myopia in children aged between eight and 12 at the beginning of treatment.
The approval of the contact lens follows a three-year randomised, controlled trial involving 135 children between eight and 12 who wore either MiSight or a conventional soft contact lens.
MiSight lenses were shown to reduce the progression of myopia and the rate of growth in axial length, with no serious adverse ocular events recorded among study participants who used the lenses.
The FDA also highlighted research showing that the proportion of vision-threatening corneal infections was similar among children and teenagers who wear soft contact lenses daily when compared to adult daily soft contact lens wearers.
The FDA has consented to the use of the contact lens to slow the progression of myopia in children aged between eight and 12 at the beginning of treatment.
The approval of the contact lens follows a three-year randomised, controlled trial involving 135 children between eight and 12 who wore either MiSight or a conventional soft contact lens.
MiSight lenses were shown to reduce the progression of myopia and the rate of growth in axial length, with no serious adverse ocular events recorded among study participants who used the lenses.
The FDA also highlighted research showing that the proportion of vision-threatening corneal infections was similar among children and teenagers who wear soft contact lenses daily when compared to adult daily soft contact lens wearers.
Comments (0)
You must be logged in to join the discussion. Log in